Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Pembrolizumab plus mFOLFOX7 of FOLFIRI bij MSS/MMR-proficiënt mCRC
okt 2024 | Immuuntherapie, Maag-darm-leveroncologie